Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.64 |
| ▸ | AXL | P30530 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 11/20 | 0.62 |
| ▸ | KDR | P35968 | 9/20 | 0.62 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.62 |
| ▸ | FLT4 | P35916 | 2/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.61 |
| ▸ | STK17B | O94768 | 1/20 | 0.61 |
| ▸ | STK10 | O94804 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097860 | 1.00 | EGFR (0.64) | EGFRAXLSRCKDREHMT2 | |
| Hydrochloric Acid SCHEMBL6432089 | 0.99 | EGFR (0.62) | EGFRAXLSRCKDREHMT2 | |
| SCHEMBL23743942 | 0.94 | KDR (0.63) | EGFRAXLSRCKDREHMT2 | |
| SCHEMBL29908858 | 0.94 | KDR (0.63) | EGFRAXLSRCKDREHMT2 | |
| SCHEMBL28492612 | 0.94 | KDR (0.63) | EGFRAXLSRCKDREHMT2 | |
| SCHEMBL8526894 | 0.90 | EHMT2 (0.76) | EGFRKDREHMT2EHMT1FLT4 | |
| SCHEMBL29636829 | 0.90 | EHMT2 (0.76) | EGFRKDREHMT2EHMT1FLT4 | |
| Hydrochloric Acid SCHEMBL6433786 | 0.89 | EHMT2 (0.74) | EGFRKDREHMT2EHMT1FLT4 | |
| SCHEMBL2152700 | 0.89 | EHMT2 (0.64) | EGFRAXLSRCKDREHMT2 | |
| SCHEMBL2748129 | 0.89 | EHMT2 (0.74) | EGFRSRCKDREHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2339918-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GlaxoSmithKline LLC (US) | 2011-07-06 | — | — | EP | claimed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | claimed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | claimed |
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4448510-A1 | INHIBITORS OF MET KINASE | Kinnate Biopharma Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118742542-A | Inhibitors of MET kinase | 金耐特生物制药公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753395-B2 | Inhibitors of MET kinase | KINNATE BIOPHARMA INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023114809-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-6977259-B2 | Quinoline derivatives and their use as aurora 2 kinase inhibitors | ASTRAZENECA AB (SE) | 2005-12-20 | — | — | US | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20030105129-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | US | disclosed |
| EP-1294709-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS AURORA 2 KINASE INHIBITORS | AstraZeneca AB (SE) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001055116-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS AURORA 2 KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-08-02 | — | — | WO | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | EGFR 35/4885AXL 133/4885SRC 46/4885 |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | EGFR 8/4885AXL 165/4885SRC 13/4885 |
| US-11753395-B2 | Inhibitors of MET kinase | MET, RET, MERTK | EGFR 8/4885AXL 165/4885SRC 13/4885 |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | EGFR 8/4885AXL 165/4885SRC 13/4885 |
| US-20030105129-A1 | Chemical compounds | AURKC, AURKA, AURKB | EGFR 83/4885AXL 461/4885SRC 114/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | EGFR 2315/4885AXL 3026/4885SRC 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.